Last reviewed · How we verify
NMS-1286937
At a glance
| Generic name | NMS-1286937 |
|---|---|
| Sponsor | Nerviano Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer (EARLY_PHASE1)
- Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms (PHASE1)
- Onvansertib + Paclitaxel In TNBC (PHASE1, PHASE2)
- Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMS-1286937 CI brief — competitive landscape report
- NMS-1286937 updates RSS · CI watch RSS
- Nerviano Medical Sciences portfolio CI